Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055241 | 1.00 | DPP4 (0.37) | DPP4APPSLC7A5FFAR1AAK1 | |
| SCHEMBL6032244 | 0.89 | AAK1 (0.35) | DPP4APPSLC7A5AAK1 | |
| SCHEMBL6246072 | 0.83 | CYP2C19 (0.39) | AAK1 | |
| SCHEMBL3453796 | 0.82 | DPP4 (0.37) | DPP4APPSLC7A5FFAR1AAK1 | |
| SCHEMBL28937621 | 0.79 | FFAR1 (0.33) | DPP4FFAR1 | |
| SCHEMBL17513198 | 0.78 | FFAR1 (0.41) | APPFFAR1AAK1 | |
| SCHEMBL28284788 | 0.77 | DPP4 (0.41) | DPP4 | |
| SCHEMBL28032950 | 0.77 | DPP4 (0.41) | DPP4 | |
| SCHEMBL27773550 | 0.76 | GABBR2 (0.42) | DPP4SLC7A5AAK1 | |
| SCHEMBL28304220 | 0.73 | DPP4 (0.33) | DPP4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109608348-A | A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid | 凯瑞斯德生化(苏州)有限公司 | 2019-04-12 | — | — | CN | claimed |
| CN-106801043-B | A kind of recombination transaminase and its preparation method and application | 江苏阿尔法药业有限公司 | 2019-08-06 | — | — | CN | disclosed |
| CN-109608348-A | A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid | 凯瑞斯德生化(苏州)有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-109608348-A | A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid | 凯瑞斯德生化(苏州)有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-109608348-A | A kind of synthetic method of (R) -3- t-butoxycarbonyl amino -4- (2,4,5- trifluorophenyl) butyric acid | 凯瑞斯德生化(苏州)有限公司 | 2019-04-12 | — | — | CN | disclosed |
| CN-106124667-B | A kind of methods of the separation determination Xi Gelieting in relation to substance | 上海应用技术学院 | 2018-07-31 | — | — | CN | disclosed |
| CN-106124667-A | A kind of method that separation determination sitagliptin has related substance | 上海应用技术学院 | 2016-11-16 | — | — | CN | disclosed |
| CN-103403008-B | The preparation method of sitagliptin intermediate | ST PHARM Co.,Ltd. (KR) | 2015-09-30 | — | — | CN | disclosed |
| EP-2665728-B1 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | ST PHARM CO LTD (KR) | 2015-07-22 | — | — | EP | disclosed |
| US-9006436-B2 | Preparation method of intermediate of sitagliptin | ST PHARM CO., LTD. (KR) | 2015-04-14 | — | — | US | disclosed |
| US-20140005394-A1 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | ST PHARM CO., LTD (KR) | 2014-01-02 | — | — | US | disclosed |
| EP-2665728-A2 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | ST Pharm Co. Ltd. (KR) | 2013-11-27 | — | — | EP | disclosed |
| CN-103403008-A | Preparation method of intermediate of sitagliptin | ST PHARM CO LTD | 2013-11-20 | — | — | CN | disclosed |
| CN-103058888-A | Preparation method of (R)-3-t-butyloxycarboryl-amino-4-(2, 4, 5-trifluorobenzene) butyric acid | SHANGHAI PUYI CHEMICAL CO LTD | 2013-04-24 | — | — | CN | disclosed |
| CN-102159578-B | Salts of tetrahydroimidazo [1,5-a] pyrazine derivatives, preparation methods and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO | 2013-04-10 | — | — | CN | disclosed |
| WO-2012099381-A2 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | ST PHARM CO., LTD. (KR) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005394-A1 | PREPARATION METHOD OF INTERMEDIATE OF SITAGLIPTIN | DPP4, DPP7, DPP9 | DPP4 1/4885APP 2248/4885SLC7A5 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.